Meridian Diagnostics Inc. (NASDAQ:KITS) of Cincinnati, Ohioannounced that it has received clearance from FDA to beginmarketing its ImmunoCard diagnostic test for Clostridiumdifficile. This bacterium produces a very potent toxin that cancause serious complications to the digestive system. Thedisease is usually caused by an adverse reaction to antibiotictherapy.
The ImmunoCard device performs rapid individual enzymeimmunoassays and detects C. difficile directly from diarrhealstool specimens.
(c) 1997 American Health Consultants. All rights reserved.